ReviewTheranostics2025
Mesoporous nanomaterial-based smart nanoplatforms for precise therapies of ulcerative colitis: Strategies and challenges.
Review in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preliminary Study on Different Types of Solid Dispersion Excipients for Improving the Water Solubility and Physical Stability of Celecoxib.Pharmaceutics · 2026Article
- Advances in Mesoporous Silica and Hybrid Nanoparticles for Drug Delivery: Synthesis, Functionalization, and Biomedical Applications.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease predominantly impacting the rectum and colon. Because UC has a complicated pathophysiology, there is no effective treatment so far. Over the past decade, nanomedicine has undergone a remarkable transformation and expansion in its application, driven by an increasingly profound comprehension of the multifaceted functions of diverse nanomaterials. Consequently, an increasing number of these advanced materials have been utilized in the treatment of UC. Notably, mesoporous nanomaterials (MNMs) have gained significant attention due to their unique physicochemical properties, including high specific surface area, tunable pore size, large pore volume, and customizable surface chemistry. These MNMs exhibit outstanding drug-loading capacity, controlled release behavior and excellent biocompatibility, which have been demonstrated successfully overcoming the limitations of conventional therapies. With increasing research interest and translational potential, this review highlights novel strategies for UC treatment by focusing on its physiopathological characteristics and summarizes recent advancements in applying MNMs for UC therapy. The design strategies of various MNM-based smart nanoplatforms as drug carriers for UC treatment are comprehensively reviewed, with critical challenges and future trends in the development and translation of MNMs for UC therapies also outlined. This review establishes a rational framework for designing smart drug delivery systems based on mesoporous nanomaterial and provides guidance and inspiration for UC and other inflammatory disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.